Samsara BioCapital
VC Fund
Palo Alto, United States
Samsara BioCapital is a VC fund in Palo Alto focused on Biotechnology and Health Care. Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.
- Total investments:
- 189
- Last investment:
- Lead investor:
- 17%
- Fund size:
- $98M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Samsara BioCapital invests in
Stages Samsara BioCapital invests in
Countries Samsara BioCapital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $33M–$150M
- Series B
- $35M–$170M
- Post-IPO Equity
- $40M–$200M
Investment Focus
Industry
- Biotechnology 120 (63%)
- Health Care 64 (34%)
- Therapeutics 55 (29%)
- Medical 41 (22%)
- Pharmaceutical 41 (22%)
Stage
- Series B 50 (26%)
- Post-IPO Equity 42 (22%)
- Series A 37 (20%)
- Series C 20 (11%)
- Series D 9 (5%)
Country
- United States 104 (55%)
- United Kingdom 7 (4%)
- Canada 4 (2%)
- France 3 (2%)
- China 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Abraham Bassan
Partner
|
Partner | Total investments: 6 | Find email | |
Michael Dybbs
Partner
|
Partner | Total investments: 13 | Find email | |
|
Christian Richard
Head of Public Research
|
Head of Public Research | Total investments: 0 | Find email | |
Marcos Milla
Venture Partner
|
Venture Partner | Total investments: 5 | Find email | |
Srini Akkaraju
Founder
|
Founder | Total investments: 6 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $3M / Series A / Sep 30, 2026 | ||
| Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focuson areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology. | $25M / Post-IPO Equity / Aug 21, 2026 | ||
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | ||
| Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M / Series B / Jun 22, 2026 | ||
| Memento Medicines is a biotechnology company focused on the development of novel antibody therapies for ophthalmology. The company's core business model centers on licensing and advancing specialized, multi-target biologics to address high-demand clinical needs in the retinal disease landscape. Its primary value proposition rests on its leadprogram, MMT-205, a dual-action bispecific antibody engineered to simultaneously activate Tie2 receptors and inhibit VEGF. This therapeutic candidate is being clinical developed to improve treatment durability and visual outcomes for individuals suffering from neovascular age-related macular degeneration and diabetic macular edema. | $93M / Series A / Jun 18, 2026 | ||
| Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $120M / Post-IPO Equity / Jun 02, 2026 | ||
| Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M / Post-IPO Equity / May 08, 2026 | ||
| Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | ||
| Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | ||
| See all 189 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Samsara BioCapital invest in?
Samsara BioCapital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 189 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Samsara BioCapital's check size?
Samsara BioCapital typically joins rounds of $33M–$150M at Series A, $35M–$170M at Series B and $40M–$200M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Samsara BioCapital participates in.
How do I contact Samsara BioCapital?
Public channels for Samsara BioCapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Samsara BioCapital?
The team at Samsara BioCapital includes Abraham Bassan (Partner), Michael Dybbs (Partner) and Christian Richard (Head of Public Research), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
